RUA LIFE SCIENCES PLC

UNAUDITED INTERIM RESULTS 2022

For the six months ended 30 September 2022

Contents

CHAIRMAN'S STATEMENT

I am pleased to set out below an overview of the unaudited interim results of RUA Life Sciences Plc for the six months to 30 September 2022. The period has seen progress in all four business units and for the first time, the segmental reporting of the business now reflects the split amongst Biomaterials, Contract Manufacture, Vascular and Structural Heart.

Unaudited interim results for the six months to 30 September 2022

The results below are the consolidated figures for the entire group and are further analysed in the relevant segmental update. The Group has maintained the level of revenue growth seen from the first to the second half of the year to March 2022. In the six months to September 2022 revenues of £1,104,000 were achieved representing an increase of £396,000 or 56% over revenues in the six months to September 2021.

Gross margins remained high at 79% resulting in gross profit of £875,000 being reported against the £528,000 achieved last year thus contributing an additional £347,000, an uplift of 66%. Investment in the talent base of the business continued which contributed to the increase in administrative expenses from £1,658,000 last year to £1,889,000. This increase includes further investment into the Vascular business unit in particular.

The net impact of growth in turnover together with increased investment resulted in a £168,000 reduction of the group loss to £1,143,000.

Working capital continues to be tightly managed with cash at the period end amounting to £2,509,000 a reduction of £454,000 from the previous year end. Not included in this cash flow or results for the interim period is the claim for R&D Tax Credits for the year to 31 March 2022. Our policy is to account for R&D Tax Credits on a cash basis and the £328,000 claimed has yet to be received from HMRC.

Biomaterials
The Biomaterials business segment is the part of the business that holds the Intellectual Property relating to Elast-Eon™ and related polymers, and licences that IP to other medical device companies. The clinical performance of Elast-Eon products continues to be excellent, particularly in the area of Cardiac Rhythm Management leads, where over 8 million have been implanted since 2006. The most recently published data indicate that the presence of Elast-Eon lead insulation dramatically reduces the probability of abrasion malfunction in tachycardia leads at 15 years by 80%, from around 5% probability to only 1%.

The Biomaterials business saw royalty and license fee income increase by 20% compared to the first half of last year rising from £156,000 to £187,000 with the growth driven by increased volumes of Elast-Eon being purchased by licensees. The Biomaterials business is however very much second half weighted as a result of the timings of when royalty fees are recognised. In the financial year ended March 2022, 68% of Biomaterials revenue was recognised in the second half of the year.

Net margins in Biomaterials remain high with the contribution to the Group increasing from £116,000 (74%) last year to £154,000 (82%) in the current period.

Contract Manufacturing
The Contract Manufacturing business segment is the end to end, third party contract developer and manufacturer of medical devices that formed part of the RUA Medical acquisition in 2020. This business has had a very successful period growing revenues from £552,000 in the first half of last year to £917,000, an increase of 66%. We do not specifically report on the gross margins achieved in this business area but the net contribution to the group during the period amounted to £384,000 being a net contribution of 42%.

We have implemented price increases within Contract Manufacturing for the first time in almost ten years but the major growth driver was a result of increased demand for product from the major customer. This increase in itself was a result of two factors, one being the post Covid increase in hospital procedures in the key US market in particular and the other being a stock build for European markets in advance of the transition from MDD to MDR regulations. During the second half year, we

anticipate a continued growth in US orders and maintaining steady levels of European orders whilst MDR stock build is fully initiated.

Business development has progressed well within the Contract Manufacturing business, with a new manufacturing contract signed with a global business for the processing and supply of two components for its medical device portfolio. First sales have now been achieved with the first batches manufactured, passed QC and shipped to the customer under the terms of the supply agreement. There will be a gradual ramp up in volumes over the next 12 months with sales expected to stabilise between £10,000 and £12,000 a month. In addition, the business is currently working on a number of requests for quotations for both components and completed devices. These quotations are for devices that are currently in the market and as such could convert to manufacturing revenue in a relatively short period of time compared to development projects. The annualised revenue potential from these quotations could more than double the current scale of the Contract Manufacturing business.

Vascular

The Vascular business segment is currently in the development stages of commercialising the Group's range of Elast-Eon sealed vascular grafts and related products. Expensed investment into this area amounted to £619,000 during the period compared to £532,000 last year. The priorities for investment were three-fold, regulatory planning, manufacturing process and commercial preparation.

Regulatory progress has been positive but time consuming. Data had previously been submitted to the FDA on the large bore grafts which demonstrated that there was a difference in the healing process to predicate textile grafts currently in the market. These differences are arguably beneficial due to a lower inflammatory response and little or no adhesion to the device when tested in vivo. However, they were different enough for the FDA to want to have a better understanding of the healing process before allowing the devices to be marketed. Rather than convert the device to the longer and more costly PMA process, the FDA has agreed to a continuance of the 510k pre-market notification process but with additional work designed around providing additional information on the healing process. The in vivo work historically undertaken had data collected at the six-month end point and comparisons made with the predicate device. At this point, the competitor grafts were adhered to the perivascular tissue whereas the RUA grafts were encapsulated but were not adhered to the perivascular tissue. In order to provide more information on this healing process, further in vivo work will be undertaken to clarify the healing process at one and three months in addition to the six-month end point. Having agreed this process, the requirements for a human clinical study were much reduced from what they could have been and in broad terms the study will be of limited scale and utilise a single arm Performance Goal design, with the primary end point of the trial being measured at six months post operation. The regulatory team is currently working towards setting up this trial and finalising the budget. The preliminary in vivo work is currently underway however we have not yet finalised our thoughts on the best time to start the clinical trial. RUA will advise in more detail on the expected costs and revised timescales in due course but in the meantime is actively exploring opportunities to finance at least part of the clinical stages through non-dilutive funding routes and grant finance.

Product development and the manufacturing process has made significant strides over the period. The Quality Management System is in the process of being transferred to a digital eQMS system along with the purchasing process, providing both greater control and cost efficiencies that should increase with the scale of the business. Importantly, the RUA ISO 13485 quality management certification has been expanded to cover the entire group and the scope has been expanded from contract manufacture to legal device manufacturer. This is a major achievement in itself. With regard to manufacturing efficiencies, a thorough review of process steps has resulted in a significant improvement in manufacturing yield. These efficiencies should enable the current clean rooms at Irvine to have sufficient capacity to provide for anticipated launch volume requirements for straight grafts together with demand of up to 10% market share in North America. The lessons learnt from this process are now being applied to optimising the design of the larger cleanroom at the second Irvine facility.

On the commercial developments, product costings indicate that after allowing for distributor margin, RUA should be able to achieve a gross margin of around 80% on products sold. Average selling prices into hospitals range from around $900 to $3,000 depending on the type of device. With regards to the sale of grafts into hospitals in both the US and other key markets, it has always been our

strategy to work with distributors rather than establish a direct sales force. We have been in discussions with a number of parties and are confident that not only is our strategy correct but there is serious interest in partnership opportunities.

Structural Heart

This is the business segment responsible for developing the Group's polymeric heart valve technology. Expensed investment in this area amounted to £289,000, a 9% reduction on the same period last year. The reduction in spend has come about through increasing the capacity of the in-house team being more than offset by undertaking fewer tasks with outside contractors.

The focus over the past six months has been risk review and mitigation. All biological valves fail and the medical profession even has a name for it - Structural Valve Deterioration (SVD). In SVD however, the failure mode is slow, and patients develop symptoms to allow the SVD to be recognised and treated. Unlike biological valves, the failure rate of mechanical valves is very low, the problem however is the failure can be catastrophic. This phenomenon was witnessed during the 1980's with the unfortunate death of a small number of patients implanted with the Bjork Shiley mechanical valve, leading to closure of the Shiley valve business and ultimately to the market dominance of the biological valve. Testing has shown that Elast-Eon is exceptionally biostable, non-calcific and non-thrombogenic and as such has the desirable properties to avoid or at least reduce the incidence of SVD. The major task for a polymeric valve (assuming the polymer is suitable for long term implantation) is to persuade regulators, surgeons and most importantly patients that the valve should not be subject to catastrophic failure. Polymer valves have been shown to pass long term durability testing yet there remains a "fear of the new" that will require to be overcome. RUA has made major steps in improving the manufacture of 100% polymeric leaflets but has been concentrating this year on a safer, more durable alternative.

The in vivo studies carried out on the vascular grafts indicated that Elast-Eon coating the fabric of the graft performed in an identical manner to what would have been expected of pure Elast-Eon. The fatigue properties and tear resistance of the graft material were however many times better than the base Elast-Eon polymer. Based on this discovery, RUA has taken the coating technology developed for the graft and, building upon that core IP, developed a method of creating a true composite material that retains the proven blood contacting properties of Elast-Eon with much improved mechanical properties. Finite Element Analysis (FEA) modelling of the material has been very promising, indicating the material should have the necessary flexibility without the risk of delamination. The valve design developed for the 100% Elast-Eon leaflets has been evolved to take advantage of the new material properties and the initial prototypes have demonstrated very encouraging hydrodynamic results, particularly with regards to the energy required to open the valve. The final stage is to complete the engineering work on the manufacture of the valves to replace the manual manufacturing process and allow sufficient numbers of the desired quality to undergo durability testing.

Conclusion and Outlook

All four business units within the RUA portfolio have made good progress over the year to date. Biomaterials has seen revenues grow in the half year with the expectation of a similar second half weighting to performance as enjoyed last year. The Contract Manufacturing business has successfully increased unit pricing to customers and been able to increase volumes without having to increase head count. Business development has resulted in first shipments to a new global customer and the business has been asked to quote for further new business which, if successful, could more than double turnover in this area. The Vascular business has overcome the regulatory hurdles of last year and has worked closely with the FDA towards a clear regulatory plan. The time taken has been used to establish a robust manufacturing process from which the cost of manufacture will allow a very attractive margin even from the pilot plant. The commercial opportunity is in active discussion and our partnering strategy will be the subject of future updates. Structural Heart has undertaken some true inventive steps in the year to date and the device envisaged is being designed to eliminate all of the objections that have been made about polymeric heart valves.

RUA Life Sciences still has a way to go to meet all of its strategic objectives but in considering the progress of each segment of the business, each one has added value in the year to date and we look forward to this continuing in the future.

Bill Brown, Chairman
12 December 2022

CONDENSED CONSOLIDATED INTERIM INCOME STATEMENT

Six months ended 30 September 2022

		Unaudited	Unaudited	Audited
	Note	**Six months to 30 Sep 2022 GB£000**	**Six months to 30 Sep 2021 GB£000**	**Twelve months to 31 Mar 2022 GB£000**
Revenue	**2**	1,104	708	1,625
Cost of sales		(229)	(180)	(267)
Gross profit		875	528	1,358
Other income		98	37	66
Administrative expenses		(1,889)	(1,658)	(3,315)
Other expenses:				
Share-based payments		(46)	(68)	(145)
Bad debt expense		-	-	(3)
Depreciation & amortisation		(174)	(145)	(313)
Total administrative expenses		(2,109)	(1,871)	(3,776)
Operating loss		(1,136)	(1,306)	(2,352)
Finance income/(expense)		(11)	(9)	(8)
Loss before taxation		(1,147)	(1,315)	(2,360)
Taxation		4	4	293
Loss attributable to equity holders of the parent company		**(1,143)**	**(1,311)**	**(2,067)**
Loss per share (basic and diluted) – GB Pence		(5.15)	(5.91)	(9.32)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION

At 30 September 2022

	Note	Unaudited 30 Sep 2022 GB£000	Unaudited 30 Sep 2021 GB£000	Audited 31 Mar 2022 GB£000
Assets				
Non-current assets				
Goodwill	3	301	301	301
Other intangible assets	4	495	547	521
Property, plant and equipment	5	2,543	2,231	2,597
Total non-currents assets		**3,339**	**3,079**	**3,419**
Current assets				
Inventories		68	177	124
Trade and other receivables		681	866	1,120
Cash and cash equivalents		2,509	4,763	2,963
Total current assets		**3,258**	**5,806**	**4,207**
Total assets		**6,597**	**8,885**	**7,626**
Equity				
Issued capital	7	1,109	1,109	1,109
Share premium	7	11,729	11,729	11,729
Capital redemption reserve		11,840	11,840	11,840
Other reserve		(1,507)	(1,629)	(1,552)
Profit and loss account		(17,685)	(15,786)	(16,542)
Total equity attributable to equity holders of the parent company		**5,486**	**7,263**	**6,584**
Liabilities				
Non-current liabilities				
Borrowings		364	305	199
Lease liabilities		0	5	83
Deferred tax		71	159	75
Other Liabilities		140	204	174
Total non-current liabilities		**575**	**673**	**531**
Current liabilities				
Borrowings		86	60	23
Lease liabilities		4	8	39
Trade and other payables		397	847	410
Other liabilities		49	34	39
Total current liabilities		**536**	**949**	**511**
Total liabilities		**1,111**	**1,622**	**1,042**
Total equity and liabilities		**6,597**	**8,885**	**7,626**

CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENT

	Unaudited	Unaudited	Audited
	Six months to 30 Sep 2022	**Six months to 30 Sep 2021**	**Twelve months to 31 Mar 2022**
	GB£000	**GB£000**	**GB£000**
Cash flows from operating activities			
Group loss after tax	(1,143)	(1,311)	(2,067)
Adjustments for:			
Depreciation and amortisation	174	145	312
Share-based payments	46	68	145
Interest (income) / expense	9	7	8
Tax credit in year	-	-	(293)
(Increase) / decrease in trade and other receivables	439	563	(53)
(Increase) / decrease in inventories	56	(93)	(39)
Increase / (decrease) in taxation	(4)	(4)	87
Increase / (Decrease) in trade and other payables	(38)	(471)	(453)
Net cash flow from operating activities	**(461)**	**(1,096)**	**(2,353)**
Cash flows from investing activities			
Purchase of property, plant & equipment	(94)	(397)	(904)
Interest received / (paid)	(9)	(7)	(8)
Net cash flow from investing activities	**(103)**	**(404)**	**(912)**
Cash flows from financing activities			
Proceeds from borrowing	150	-	-
Repayment of loans and lease liabilities	(40)	(31)	(66)
Net cash flow from financing activities	**110**	**(31)**	**(66)**
Net increase / (decrease) in cash and cash equivalents	(454)	(1,531)	(3,331)
Cash and cash equivalents at beginning of period	2,963	6,294	6,294
Cash and cash equivalents at end of period	**2,509**	**4,763**	**2,963**

Six months ended 30 September 2022

Condensed consolidated interim statement of changes in equity

	Issued share capital GB£000	Share premium GB£000	Capital redemption reserve GB£000	Other reserve GB£000	Profit and loss account GB£000	Total equity GB£000
Balance at 31 March 2021	**12,949**	**11,729**	-	**(1,697)**	**(14,475)**	**8,506**
Transfer of deferred shares	(11,840)	-	11,840	-	-	-
Share-based payments	-	-	-	68	-	68
Transactions with owners	(11,840)	-	11,840	68	-	68
Total comprehensive income for the period	-	-	-	-	(1,311)	(1,311)
Balance at 30 September 2021	**1,109**	**11,729**	**11,840**	**(1,629)**	**(15,786)**	**7,263**
Share-based payments	-	-	-	77	-	77
Issue of equity share capital - exercise of warrants	-	-	-	-	-	-
Issue of equity share capital (net of issue costs) – fundraise	-	-	-	-	-	-
Transactions with owners	-	-	-	77	-	77
Total comprehensive loss for the period	-	-	-	-	(756)	(756)
Balance at 31 March 2022	**1,109**	**11,729**	**11,840**	**(1,552)**	**(16,542)**	**6,584**
Transfer deferred share to capital redemption reserve	-	-	-	-	**-**	**-**
Share-based payments	-	-	-	46	-	46
Transactions with owners	-	-	-	46	-	46
Total comprehensive loss for the period	-	-	-	-	(1,143)	(1,143)
Balance at 30 September 2022	**1,109**	**11,729**	**11,840**	**(1,506)**	**(17,685)**	**5,487**

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1. BASIS OF PREPARATION

General information

RUA Life Sciences plc is the ultimate parent company of the Group, whose principal activities are contract design and manufacture of medical devices and exploiting the value of its IP and know-how.

RUA Life Sciences plc is incorporated and domiciled in the UK and its registered office is c/o Davidson Chalmers Stewart LLP, 163 Bath Street, Glasgow, G2 4SQ.

Basis of preparation

These condensed consolidated interim financial statements are for the six months ended 30 September 2022 and have been prepared with regard to the requirements of IAS 34 on "Interim Financial Reporting". They do not include all of the information required for full financial statements and should be read in conjunction with the audited consolidated financial statements of the Group for the year ended 31 March 2022.

The financial information for the six months ended 30 September 2022 and the comparative figures for the six months ended 30 September 2021 are unaudited. They have been prepared on the basis of the accounting policies set out in the consolidated financial statements of the Group for the year ended 31 March 2022 and, on the recognition, and measurement principles of IFRS in issue as effective at 30 September 2022. The accounting policies have been applied consistently throughout the Group for the purposes of preparation of these condensed consolidated interim financial statements.

The figures for the year ended 31 March 2022 have been extracted from the audited statutory accounts which were approved by the Board of Directors on 8 July 2022, prepared under IFRS. The Independent Auditor's Report on the Report and Financial Statements for the year ended 31 March 2022 was unqualified but did draw attention to Note 1 of those financial statements which explains that the Group and Parent Company's ability to continue as a going concern is dependent on the execution of its business plan together with its ability to raise sufficient capital to meet capital and liquidity requirements. The auditors report did not contain any statements under sections 498(2) or 498(3) of the Companies Act 2006.

These condensed consolidated interim financial statements were approved for issue by the Board of Directors on 9 December 2022.

Going concern

The 2022 Annual Report audit report drew attention to the material uncertainty relating to going concern as follows:

"We draw attention to the going concern accounting policy in note 1 of the financial statements, which states that the RUA Life Sciences Group is loss-making and cash-consumptive, and its revenue streams have been impacted by the COVID-19 pandemic and the resulting macro-economic uncertainty and the setback of a regulatory delay for the Vascular Graft Range. These events and conditions may result in lower than forecasted revenues and increased costs associated with the regulatory delay. This increases the risk that the group will not be able to execute its business plan, which could adversely impact its ability to generate profit or raise sufficient capital to meet capital and liquidity requirements. As stated in note 1, these events or conditions, together with the requirement for financing indicate that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern. Our opinion is not modified in respect of this matter."

The Board and management have prepared and reviewed financial forecasts and cashflow requirements. The review included key assumptions, sensitivities, and contingency plans to cover

eventualities, including the associated cash flow projections. The review has been updated and also taken into consideration the potential impact of changing market conditions and other risks and uncertainty, paying particular attention to the impact of potential delays in the regulatory process of our Vascular grafts.

The Directors concluded that given the combination of the cash balance of £2.5m at 30 September 2022 and the forecast monthly cash utilisation, the Group has sufficient liquidity throughout a period of at least 12 months from the date of approval of this interim financial report.

As a result, the Directors have a reasonable expectation that the Group as a whole has adequate resources to continue in operational existence for a period of at least 12 months from the date of this interim financial report. For this reason, they continue to adopt the going concern basis in preparing the unaudited interim report for the half year ended 30 September 2022.

The financial statements do not include any adjustments that would be necessary if the group or company was unable to continue as a going concern.

Principal Risks and Uncertainties

The principal risks and uncertainties affecting the business activities of the Group remain those detailed on pages 19-22 of the Annual Report 2022, a copy of which is available on the Company's website www.rualifesciences.com

Loss per share

Loss per share has been calculated on the basis of the result for the period after tax, divided by the weighted average number of ordinary shares in issue in the period of 22,184,798. (30 September 2021: 22,184,798 and 31 March 2022: 22,184,798).

2. SEGMENTAL REPORTING

The principal activity of the RUA Life Sciences Group comprise exploiting the value of its IP & know-how, medical device contract manufacturing and development of cardiovascular devices.

Following the acquisition of RUA Medical Devices Ltd and an internal organisation and reporting review, the Board has decided the business will report by business unit segments, namely royalty and license income (Biomaterials), Contract Manufacturing, product development (Vascular) & product innovation (Structural Heart), rather than trading entities, which is consistent with both how the business will be managed and reported internally in the future.

The following analysis by segment is presented in accordance with IFRS 8 on the basis of those segments whose operating results are regularly reviewed by the Chief Operating Decision Maker (considered to be the executive chairman of the board) to assess performance and make strategic decisions about the allocation of resources. Segmental results are calculated on an IFRS basis.

A brief description of the segments of the business is as follows:

• Biomaterials – Licensor of Elast-Eon™ polymers to the medical device industry.
• Contract Manufacturing – End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.
• Vascular – Development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products.
• Structural Heart – Development of the Group's tri leaflet polymeric heart valves.

Operating results which cannot be allocated to an individual segment are recorded as central and unallocated.

Analysis of revenue by income stream	Unaudited **Six months to 30 Sep 2022 GB£000**	Unaudited **Six months to 30 Sep 2021 GB£000**	Audited **Twelve months to 31 Mar 2022 GB£000**
Biomaterials	187	156	487
Contract Manufacture	917	552	1,138
Vascular	-	-	-
Structural Heart	-	-	-
Total	**1,104**	**708**	**1,625**

Analysis of revenue by geographical location	Unaudited **Six months to 30 Sep 2022 GB£000**	Unaudited **Six months to 30 Sep 2021 GB£000**	Audited **Twelve months to 31 Mar 2022 GB£000**
Europe	6	43	192
USA	1,072	643	1,379
RoW	26	22	54
Total	**1,104**	**708**	**1,625**

The Group's revenue for six months to 30 September 2022 is segmented as follows:

Analysis of revenue by income stream

	Unaudited Biomaterials GB£000	Unaudited Contract Manufacture GB£000	Unaudited Vascular GB£000	Unaudited Structural Heart GB£000	Unaudited Central and unallocated GB£000	Unaudited Total GB£000
Contract Design & Manufacture of Medical Devices	-	917	-	-	-	917
Royalty revenue	187	-	-	-	-	187
Total	**187**	**917**	**-**	**-**	**-**	**1,104**

Analysis of revenue by geographical location

	Unaudited Biomaterials GB£000	Unaudited Contract Manufacture GB£000	Unaudited Vascular GB£000	Unaudited Structural Heart GB£000	Unaudited Central and unallocated GB£000	Unaudited Total GB£000
Europe	7	-1	-	-	-	6
USA	154	918	-	-	-	1,072
RoW	26	-	-	-	-	26
Total	**187**	**917**	**-**	**-**	**-**	**1,104**

Restatement of Analysis of revenue by income stream six month to 30 September 2021 is as follows:

Analysis of revenue by income stream

	Unaudited Biomaterials GB£000	Unaudited Contract Manufacture GB£000	Unaudited Vascular GB£000	Unaudited Structural Heart GB£000	Unaudited Central and unallocated GB£000	Unaudited Total GB£000
Contract Design & Manufacture of Medical Devices	-	552	-	-	-	552
Royalty revenue	156	-	-	-	-	156
Total	**156**	**552**	**-**	**-**	**-**	**708**

Analysis of revenue by geographical location

	Unaudited Biomaterials GB£000	Unaudited Contract Manufacture GB£000	Unaudited Vascular GB£000	Unaudited Structural Heart GB£000	Unaudited Central and unallocated GB£000	Unaudited Total GB£000
Europe	-	44	-	-	-	44
USA	134	508	-	-	-	642
RoW	22	-	-	-	-	22
Total	**156**	**552**	**-**	**-**	**-**	**708**

Segment Analysis for period to 30 September 2022

	Unaudited Biomaterials GB£000	Unaudited Contract Manufacture GB£000	Unaudited Vascular GB£000	Unaudited Structural Heart GB£000	Unaudited Central and unallocated GB£000	Unaudited Total GB£000
Consolidated group revenues from external customers	187	917	-	-	-	1,104
Contributions to group operating loss	154	384	(619)	(289)	(766)	(1,136)
Depreciation	-	139	-	8	1	148
Amortisation of intangible assets	-	22	-	-	4	26
Segment assets	90	4,012	-	152	2,343	6,597
Segment liabilities	2	897	34	4	174	1,111
Intangible assets – goodwill	-	301	-	-	-	301
Other intangible assets	-	419	-	-	76	495
Additions to non-current assets	-	94	-	-	-	94

Restatement of Segment Analysis six month to 30 September 2021 is as follows:

Segment Analysis 2021

	Unaudited Biomaterials GB£000	Unaudited Contract Manufacture GB£000	Unaudited Vascular GB£000	Unaudited Structural Heart GB£000	Unaudited Central and unallocated GB£000	Unaudited Total GB£000
Consolidated group revenues from external customers	156	552	-	-	-	708
Contributions to group operating loss	116	79	(532)	(317)	(652)	(1,306)
Depreciation	-	117	-	-	1	118
Amortisation of intangible assets	-	22	-	-	5	27
Segment assets	167	3,763	-	153	4,802	8,885
Segment liabilities	6	1,333	44	26	213	1,622
Intangible assets – goodwill	-	301	-	-	-	301
Other intangible assets	-	462	-	-	85	547
Additions to non-current assets	-	313	-	-	84	397

3. GOODWILL

The final valuation following the acquisition of RUA Medical Devices Limited gave rise to adjustments being required to the value of intangibles recognised in the Interim Report for the six months ended 30 September 2020 (as noted in note 5 below), and lead to the following goodwill being recognised:

No impairment review has been carried out in the six-month period.

	GB£000
Gross carrying amount	
Balance at 31 March 2021	**301**
Balance at 31 March 2022	301
Balance at 30 September 2022	**301**

4. INTANGIBLE ASSETS

	Development costs	Intellectual property	Customer related	Technology based	Total
Gross carrying amount					
At 31 March 2021	**337**	**3,325**	**247**	**141**	**4,050**
At 30 September 2021	**337**	**3,325**	**247**	**141**	**4,050**
At 31 March 2022	**337**	**3,325**	**247**	**141**	**4,050**
At 30 September 2022	**337**	**3,325**	**247**	**141**	**4,050**
Amortisation and impairment					
At 31 March 2021	**334**	**3,099**	**29**	**14**	**3,476**
Charge for the period	2	4	14	7	27
At 30 September 2021	**336**	**3,103**	**43**	**21**	**3,503**
Charge for the period	1	3	15	7	26
At 31 March 2022	**337**	**3,106**	**58**	**28**	**3,529**
Charge for the period	-	4	15	7	26
At 30 September 2022	**337**	**3,110**	**73**	**35**	**3,555**
Net book value					
At 30 September 2021	1	222	204	120	547
At 31 March 2022	-	219	189	113	521
At 30 September 2022	**-**	**215**	**174**	**106**	**495**

5. PROPERTY, PLANT AND EQUIPMENT

	Land & Buildings GB£000	Plant & Machinery GB£000	Office Equipment GB£000	Motor Vehicles GB£000	Total GB£000
Cost					
At 31 March 2021	**944**	**1,114**	**63**	**28**	**2,149**
Additions	28	361	8	-	**397**
At 30 September 2021	**972**	**1,475**	**71**	**28**	**2,546**
Additions	363	139	8	(3)	**507**
At 31 March 2022	**1,335**	**1,614**	**79**	**25**	**3,053**
Additions	-	80	14	-	**94**
At 30 September 2022	**1,335**	**1,694**	**93**	**25**	**3,147**
Depreciation					
At 31 March 2021	**58**	**112**	**18**	**9**	**197**
Charge	29	79	7	3	118
At 30 September 2021	**87**	**191**	**25**	**12**	**315**
Charge	33	96	8	4	**141**
At 31 March 2022	**120**	**287**	**33**	**16**	**456**
Charge	30	106	8	4	148
At 30 September 2022	**150**	**393**	**41**	**20**	**604**
Net book value					
At 30 September 2021	885	1,284	46	16	2,231
At 31 March 2022	1,215	1,327	46	9	2,597
At 30 September 2022	**1,185**	**1,301**	**52**	**5**	**2,543**

Included in the net carrying amount of property plant and equipment are right-of-use assets as follows:

	30 September 2022 GB£000
Plant & Machinery	**131**
Motor vehicles	**5**
Total right-of-use assets	**136**

7. ISSUED SHARE CAPITAL

The Company's issued share capital at 30 September 2022 comprises 22,184,798 Ordinary Shares of which none are held in treasury.

8. INTERIM ANNOUNCEMENT

The interim results announcement was released on 12 December 2022. A copy of this Interim Report is also available on the Company's website www.rualifesciences.com.

BOARD OF DIRECTORS AND ADVISORS

DIRECTORS

W Brown – Executive Chairman
C Stretton – Group Managing Director
L Smith – Group CFO
I Anthony – Clinical and Regulatory Affairs
J McKenna – Director of Marketing
I **Ardill** – Non-Executive Director
G Berg – Non-Executive Director
J Ely – Non-Executive Director

COMPANY SECRETARY

K M Full FCCA

HEAD OFFICE

2 Drummond Crescent
Irvine
Ayrshire
KA11 5AN

web: www.rualifesciences.com
email: info@rualifesciences.com

REGISTERED OFFICE

c/o Davidson Chalmers Stewart LLP
163 Bath Street
Glasgow
G2 4SQ

NOMINATED ADVISER AND BROKER

Cenkos Securities plc
6,7,8 Tokenhouse Yard
London
EC2R 7AS

REGISTRARS

Equiniti Limited
Aspect House
Spencer Road
West Sussex
BN99 6DA

LAWYERS

Davidson Chalmers Stewart
163 Bath Street
Glasgow
G2 4SQ

Burness Paull LLP
50 Lothian Road
Festival Square
Edinburgh
EH3 9WJ

INDEPENDENT AUDITOR

Grant Thornton UK LLP
Statutory Auditor
Chartered Accountants
Monteith House
110 Queen Street
Glasgow
G1 3BX

Registered in Scotland, Company No.SC170071

Financial statements will be available to Shareholders from the Company Website, along with copies of the announcement. Dealings permitted on Alternative Investment Market (AIM) of the London Stock Exchange.